MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hockerman, G. H.
Right arrow Articles by Catterall, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hockerman, G. H.
Right arrow Articles by Catterall, W. A.

Vol. 58, Issue 6, 1264-1270, December 2000

Molecular Determinants of Diltiazem Block in Domains IIIS6 and IVS6 of L-type Ca2+ Channels

Gregory H. Hockerman, Nejmi Dilmac, Todd Scheuer, and William A. Catterall

Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana (G.H.H., N.D.); and Department of Pharmacology, University of Washington, Seattle, Washington (T.S., W.A.C.)

The benzothiazepine diltiazem blocks ionic current through L-type Ca2+ channels, as do the dihydropyridines (DHPs) and phenylalkylamines (PAs), but it has unique properties that distinguish it from these other drug classes. Wild-type L-type channels containing alpha 1CII subunits, wild-type P/Q-type channels containing alpha 1A subunits, and mutants of both channel types were transiently expressed in tsA-201 cells with beta 1B and alpha 2delta subunits. Whole-cell, voltage-clamp recordings showed that diltiazem blocks L-type Ca2+ channels approximately 5-fold more potently than it does P/Q-type channels. Diltiazem blocked a mutant P/Q-type channel containing nine amino acid changes that made it highly sensitive to DHPs, with the same potency as L-type channels. Thus, amino acids specific to the L-type channel that confer DHP sensitivity in an alpha 1A background also increase sensitivity to diltiazem. Analysis of single amino acid mutations in domains IIIS6 and IVS6 of alpha 1CII subunits confirmed the role of these L-type-specific amino acid residues in diltiazem block, and also indicated that Y1152 of alpha 1CII, an amino acid critical to both DHP and PA block, does not play a role in diltiazem block. Furthermore, T1039 and Y1043 in domain IIIS5, which are both critical for DHP block, are not involved in block by diltiazem. Conversely, three amino acid residues (I1150, M1160, and I1460) contribute to diltiazem block but have not been shown to affect DHP or PA block. Thus, binding of diltiazem to L-type Ca2+ channels requires residues that overlap those that are critical for DHP and PA block as well as residues unique to diltiazem.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics